Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-4681
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma ; day:19 ; month:4 ; year:2017 ; pages:1-9
Annals of surgical oncology ; (19.4.2017), 1-9
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Anderegg, M. C. J.
- Beteiligte Personen und Organisationen
-
Sluis, P. C. van der
Ruurda, J. P.
Gisbertz, S. S.
Hulshof, M. C. C. M.
Vulpen, M. van
Mohammed, N. Haj
Laarhoven, H. W. M. van
Wiezer, M. J.
Los, M.
Berge Henegouwen, M. I. van
Hillegersberg, R. van
SpringerLink (Online service)
- DOI
-
10.1245/s10434-017-5827-1
- URN
-
urn:nbn:de:1111-201705044536
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Anderegg, M. C. J.
- Sluis, P. C. van der
- Ruurda, J. P.
- Gisbertz, S. S.
- Hulshof, M. C. C. M.
- Vulpen, M. van
- Mohammed, N. Haj
- Laarhoven, H. W. M. van
- Wiezer, M. J.
- Los, M.
- Berge Henegouwen, M. I. van
- Hillegersberg, R. van
- SpringerLink (Online service)
Ähnliche Objekte (12)
Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer
Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer
Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
Perioperative immunotherapy for resectable non-small-cell lung cancer
Role of tight junction proteins in gastroesophageal reflux disease
Two decades of gastric and gastroesophageal junction cancer surgery
Li Fraumeni Syndrome predisposes to gastro-esophageal junction tumours
Treatment for locally resectable stage IIIC1r cervical cancer: surgery or chemoradiotherapy?
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction
Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer
Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer
Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
Perioperative immunotherapy for resectable non-small-cell lung cancer
Role of tight junction proteins in gastroesophageal reflux disease
Two decades of gastric and gastroesophageal junction cancer surgery
Li Fraumeni Syndrome predisposes to gastro-esophageal junction tumours
Treatment for locally resectable stage IIIC1r cervical cancer: surgery or chemoradiotherapy?
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction
Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer
Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer
Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
Perioperative immunotherapy for resectable non-small-cell lung cancer
Role of tight junction proteins in gastroesophageal reflux disease
Two decades of gastric and gastroesophageal junction cancer surgery
Li Fraumeni Syndrome predisposes to gastro-esophageal junction tumours
Treatment for locally resectable stage IIIC1r cervical cancer: surgery or chemoradiotherapy?
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction
Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial